This antibody, which can bind to Carbonic Anhydrase IX (CAIX), is useful in the diagnosis and treatment of cancer and in conditions associated with hypoxia and/or elevated CAIX activity. It has cross-reactivity with Human, Mouse.
Figure 1 Binding specificity of the purified constructs.
Flow cytometric analysis of Fab MSC 3 on human (A) or murine (B) cell lines induced for 48 h in 0.2% 02 (grey) or normoxia (white).
Figure 2 Carbonic anhydrase activity, normalized to a scale where activity measured in HCTl 16-CAIX and HCTl 16-EV membrane fragments are one and zero, respectively.
Asterisks denote significant reduction in activity (MSC5, MSC 10„MSC12 and MSC8 Fab antibodies).
Boreel, Daan F., et al. "Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models." Molecular Pharmaceutics 20.4 (2023): 2245-2255. https://doi.org/10.1021/acs.molpharmaceut.3c00045
This study investigates the quantitative imaging of hypoxic CAIX-positive tumor areas with low immune cell infiltration in syngeneic mouse tumor models. The research focuses on developing a radiolabeled antibody targeting murine CAIX to visualize chronic hypoxia in these models and study the immune cell population in these hypoxic areas. Using the anti-mCAIX antibody (MSC3) conjugated to diethylenetriaminepentaacetic acid (DTPA) and radiolabeled with indium-111 ([111In]In-MSC3), the study demonstrated that this tracer specifically binds to CAIX-expressing cells in vitro and accumulates in CAIX-positive areas in vivo. The study highlighted that these CAIX-positive areas are characterized by reduced infiltration of immune cells, underscoring the immunosuppressive nature of chronic hypoxia in tumors. The findings suggest that this imaging technique can be used to optimize immuno- and radiotherapy efficacy by visualizing CAIX expression before or during hypoxia-targeted treatments.
Creative Biolabs provided the crucial human IgG1 anti-mouse CAIX antibody (Cat# TAB-1458CL) for this research. This antibody was pivotal in enabling the conjugation and radiolabeling processes necessary for developing the [111In]In-MSC3 tracer. By facilitating specific binding to CAIX-expressing cells and accumulation in hypoxic tumor regions, the MSC3 antibody allowed for the effective visualization and analysis of CAIX-positive hypoxic areas. This contribution was instrumental in advancing the study's objective of using CAIX as a biomarker for chronic hypoxia and its associated immunosuppressive microenvironment in preclinical models.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-707 | Anti-CAIX/CA9 Recombinant Antibody (Girentuximab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
TAB-H43 | Anti-Human CA9 Recombinant Antibody (TAB-H43) | ELISA, IP, IF, Inhib | IgG1 - kappa |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-1458CL, RRID: AB_3111834)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.